Physician profile
David L Hall
NPI 1962486381
$10,363.59
in general payments reported to CMS, 2019-2025
55 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $607 · 2021: $1,330 · 2022: $1,758 · 2023: $1,895 · 2024: $1,780 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,209 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,208.67 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.26 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,024.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $824.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $808.50 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $723.93 | 2021-2025 | |
| Abbott Laboratories | $542.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $389.59 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $377.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.32 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $371.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $348.88 | 2019-2025 | |
| Amarin Pharma, INC. | $290.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $220.57 | 2019-2023 | Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $219.03 | 2021-2024 | Nexletol, Nexlizet |
| Biohaven Pharmaceutical Holding Company LTD. | $204.63 | 2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.